Editor's Corner

As we gear up for our webinar on economic development March 1st at 1:30 EST, I'd like to know some of the questions you'd most like to hear answered. We've been seeing states and countries around the globe blueprinting some ambitious plans to spur biotech development, and a lot of those programs could make a material difference for an emerging biotech company. So email me any suggestions you might have. And don't forget to register ahead of time.

In addition, I'm planning to launch a new weekly newsletter on the regulatory world in early April. We're going to focus on the FDA as well as regulators around the globe, and any suggestions you may have on content would be valued. -John Carroll

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.